MRI中钆基对比剂首次与重复急性不良反应的评估:一项回顾性研究
该单中心回顾性研究评估2012年1月至2019年9月MRI静脉注射钆基对比剂后急性不良反应。首次急性不良反应发生率为0.31%(129/41827次注射),重复急性不良反应发生率3.6%,显著高于首次,但均为轻度。不同钆基对比剂过敏样反应和化学毒性反应的OR值不同,类固醇预处理未显示效果。
要点
- 首次急性不良反应发生率为0.31%(129/41827次注射),患者水平为0.70%(18431例中)。
- 有急性不良反应史者重复发生率为3.6%,显著高于首次0.31%(p<0.001),但均为轻度。
- 以钆特酸葡胺为参照,三种钆基对比剂过敏样反应OR为3.27至8.03;钆特醇化学毒性反应OR为3.75。
核心结论
- 首次急性不良反应的发生与所用钆基对比剂及其他因素相关;重复急性不良反应发生率高于首次,但严重程度均为轻度;类固醇预处理未显示效果。
研究设计与样本
- 单中心回顾性研究,评估2012年1月至2019年9月所有MRI静脉注射钆基对比剂,共41827次注射、18431例患者;首次急性不良反应采用多变量回归模型(广义估计方程)分析,重复急性不良反应采用Fisher精确检验。
诊断标准与关键数值
- 首次急性不良反应发生率0.31%(129/41827次注射),患者水平0.70%(18431例中)。
- 以钆特酸葡胺为参照,三种钆基对比剂过敏样反应OR范围为3.27至8.03(p=0.012至<0.001)。
- 钆特醇化学毒性反应OR为3.75(p=0.001)。
- 有急性不良反应史者重复轻度急性不良反应发生率为3.6%,显著高于首次的0.31%(p<0.001)。
- 类固醇预处理未显示效果。
临床应用与阅片要点
- 有急性不良反应史的患者重复发生急性不良反应的风险较高(3.6% vs 首次0.31%),但均为轻度。
- 不同钆基对比剂的过敏样反应和化学毒性反应风险不同,以钆特酸葡胺为参照时三种对比剂过敏样反应OR为3.27至8.03。
- 门诊患者化学毒性反应OR较低,头颈部和乳腺MRI化学毒性反应OR较高(p<0.05)。
- 年龄的OR为0.99(p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To identify gadolinium-based contrast agents (GBCAs)-related and patient-related risk factors for acute adverse reactions (AARs), and to examine the incidence and severity of repeated AARs.
METHODS: This study retrospectively evaluated all intravenous GBCA injections in MRI studies at a single institution from January 2012 to September 2019. First-time AARs in patients without a past history of AARs and risk factors were assessed using multivariable regression models with generalized estimating equations. For patients with a past history of AAR(s), we evaluated the incidence of repeated AARs using the Fisher's exact test, as well as the severity of these repeated AARs.
RESULTS: First-time AARs occurred in 129 of 41,827 GBCA injections (0.31 %; 0.70 % of 18,431 patients). With gadoterate meglumine as the reference, the odds ratio (OR) for allergic-like reactions to three GBCAs ranged from 3.27 to 8.03 (p = 0.012 to <0.001). For chemotoxic reactions, the OR was 3.75 (p = 0.001) for gadoteridol. Outpatients had a lower OR for chemotoxic reactions, while higher ORs were observed in head/neck and breast MRI (p < 0.05). The OR for age was 0.99 (p < 0.05). Patients with a past history of AAR(s) had a 3.6 % incidence of mild repeated AARs for all GBCA, significantly higher than the 0.31 % in first-time AARs (p < 0.001). No effectiveness was found for steroid premedication.
CONCLUSION: The occurrence of first-time AARs was related to the GBCA used and other factors. The incidence of repeated AARs was higher than first-time AARs, though all were mild in severity.
引用
- Fukushima Y, Ozaki D, Taketomi-Takahashi A, et al. Assessment of first-time and repeated acute adverse reactions to gadolinium-based contrast agents in MRI: A retrospective study. Eur J Radiol. 2024. PMID: 38761445. doi:10.1016/j.ejrad.2024.111504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。